A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
Clinical trial NCT07652073 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07652073
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-15
- Primary completion
- 2027-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.